Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio, Inc. (Nasdaq: ACET) announced the grant of 195,898 non-qualified stock options to Nick Harvey, appointed as Chief Financial Officer on September 16, 2020. This option aims to incentivize Mr. Harvey's employment, vesting over four years. The first 25% will vest after one year, with the remaining 75% vesting monthly. Adicet focuses on allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response through engineered T cells.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Nick Harvey as its new Chief Financial Officer. Harvey brings over 20 years of experience in financial operations and capital markets, having previously served at Centrexion Therapeutics and Radius Health, where he played a key role in its IPO. The company's leadership expressed confidence that Harvey's expertise will support Adicet's strategic growth and advancement of its gamma delta T cell therapy platform.
Adicet Bio (Nasdaq: ACET) announced that CEO Chen Schor will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 8:40 AM ET. A live audio webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
The company specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing immune responses with engineered T cells for better tumor targeting.